Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Sonova to increase presence in US market:
Acquisition of leading audiological care network
Sonova to increase presence in US market: Acquisition of leading audiological care network
Sonova to increase presence in US market: Acquisition of leading audiological care network
Sonova verstärkt Präsenz auf dem US-Markt:
Akquisition einer führenden Kette von Hörakustikgeschäften
Sonova verstärkt Präsenz auf dem US-Markt: Akquisition einer führenden Kette von Hörakustikgeschäften
Sonova verstärkt Präsenz auf dem US-Markt: Akquisition einer führenden Kette von Hörakustikgeschäften
EQS-Adhoc: Cosmo Pharmaceuticals Announces Hiring of Head of Investor Relations and Senior Leadership Change
EQS-Adhoc: Cosmo Pharmaceuticals Announces Hiring of Head of Investor Relations and Senior Leadership Change
EQS-Adhoc: Cosmo Pharmaceuticals Announces Hiring of Head of Investor Relations and Senior Leadership Change
EQS-Adhoc: Cosmo Pharmaceuticals gibt die Einstellung einer Head of Investor Relations und einen Wechsel im Management-Team bekannt
EQS-Adhoc: Cosmo Pharmaceuticals gibt die Einstellung einer Head of Investor Relations und einen Wechsel im Management-Team bekannt
EQS-Adhoc: Cosmo Pharmaceuticals gibt die Einstellung einer Head of Investor Relations und einen Wechsel im Management-Team bekannt
EQS-Adhoc: COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A ANNOUNCE SETTLEMENT OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES IN CASSIOPEA S.P.A.
EQS-Adhoc: COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A ANNOUNCE SETTLEMENT OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES IN CASSIOPEA S.P.A.
EQS-Adhoc: COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A ANNOUNCE SETTLEMENT OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES IN CASSIOPEA S.P.A.
EQS-News: Straumann Group präsentiert Weiterentwicklung der Strategie zur Erreichung des langfristigen Umsatzziels von CHF 5 Mrd.
EQS-News: Straumann Group präsentiert Weiterentwicklung der Strategie zur Erreichung des langfristigen Umsatzziels von CHF 5 Mrd.
EQS-News: Straumann Group präsentiert Weiterentwicklung der Strategie zur Erreichung des langfristigen Umsatzziels von CHF 5 Mrd.
EQS-News: Straumann Group presents evolved strategy to achieve its long-term revenue ambition of CHF 5 billion
EQS-News: Straumann Group presents evolved strategy to achieve its long-term revenue ambition of CHF 5 billion
EQS-News: Straumann Group presents evolved strategy to achieve its long-term revenue ambition of CHF 5 billion
EQS-News: Sonova nominates Julie Tay for election as a new member of
the Board of Directors
EQS-News: Sonova nominates Julie Tay for election as a new member of the Board of Directors
EQS-News: Sonova nominates Julie Tay for election as a new member of the Board of Directors
EQS-News: Julie Tay neu zur Wahl in den Sonova Verwaltungsrat nominiert
EQS-News: Julie Tay neu zur Wahl in den Sonova Verwaltungsrat nominiert
EQS-News: Julie Tay neu zur Wahl in den Sonova Verwaltungsrat nominiert
EQS-Adhoc: COSMO PHARMACEUTICALS N.V. UND CASSIOPEA S.P.A. VERÖFFENTLICHEN ENDGÜLTIGE ERGEBNISSE DES ÖFFENTLICHEN UMTAUSCHANGEBOTS FÜR ALLE SICH IM PUBLIKUM BEFINDENDEN AKTIEN DER CASSIOPEA S.P.A.
EQS-Adhoc: COSMO PHARMACEUTICALS N.V. UND CASSIOPEA S.P.A. VERÖFFENTLICHEN ENDGÜLTIGE ERGEBNISSE DES ÖFFENTLICHEN UMTAUSCHANGEBOTS FÜR ALLE SICH IM PUBLIKUM BEFINDENDEN AKTIEN DER CASSIOPEA S.P.A.
EQS-Adhoc: COSMO PHARMACEUTICALS N.V. UND CASSIOPEA S.P.A. VERÖFFENTLICHEN ENDGÜLTIGE ERGEBNISSE DES ÖFFENTLICHEN UMTAUSCHANGEBOTS FÜR ALLE SICH IM PUBLIKUM BEFINDENDEN AKTIEN DER CASSIOPEA S.P.A.
EQS-Adhoc: COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A. PUBLISH DEFINITIVE FINAL RESULTS OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES OF CASSIOPEA S.P.A.
EQS-Adhoc: COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A. PUBLISH DEFINITIVE FINAL RESULTS OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES OF CASSIOPEA S.P.A.
EQS-Adhoc: COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A. PUBLISH DEFINITIVE FINAL RESULTS OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES OF CASSIOPEA S.P.A.
EQS-News: Straumann Group Capital Markets Day 2021
EQS-News: Straumann Group Capital Markets Day 2021
EQS-News: Straumann Group Capital Markets Day 2021
3 Small Cap Stocks That Insiders Are Buying: https://www.marketbeat.com/logos/articles/med_20240903112000_chart-grwg-932025.png
3 Small Cap Stocks That Insiders Are Buying

Insider buying is interesting because it highlights stocks bought by people who know the most about a business. Insiders buying small-cap names are more interesting because of the outlook for

3 Stocks to Buy for a Soft Landing, If There Is One: https://www.marketbeat.com/logos/articles/med_20240815092649_3-stocks-to-buy-for-a-soft-landing-if-there-is-one.jpg
3 Stocks to Buy for a Soft Landing, If There Is One

Recent economic data is reigniting talk about a soft landing for the economy. That means that the Federal Reserve’s monetary policy regarding interest rates is neither too restrictive nor too

HealthEquity Stock: Leading Health Savings Account Investment
HealthEquity Stock: Leading Health Savings Account Investment

HealthEquity Inc (NASDAQ: HQY) is one of the nation’s largest providers of health savings accounts (HSA) and consumer-directed benefits (CDB) services. Its platform enables individuals to open

Johnson & Johnson is as Cheap as it’s Going to Get
Johnson & Johnson is as Cheap as it’s Going to Get

Shares of Johnson & Johnson (NYSE: JNJ) are as cheap as they will get. The stock is down in premarket trading following the Q1 release, but there is a bottom in play and reality to face. Trading

S&P 500's surge to new highs: Bull trap hiding in plain sight?
S&P 500's surge to new highs: Bull trap hiding in plain sight?

The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) is trading at new highs, but as the sharp pullback on February 13 showed, the rally may be showing signs of cracking.

The market went back into rally

Med-tech stock Conmed dips ahead of big Q4 report...opportunity?
Med-tech stock Conmed dips ahead of big Q4 report...opportunity?

When Utica, NY-based medical technology company CONMED Corporation (NYSE:CNMD) reports fourth quarter financials after the close on Wednesday, it is expected to post some of its best growth in

HCA Healthcare Rallies: Weight-loss drugs really a big threat?
HCA Healthcare Rallies: Weight-loss drugs really a big threat?

Hospital chain HCA Healthcare, Inc. (NYSE: HCA) has been working on a bullish base and even managed to post gains in a week when the SPDR S&P 500 ETF Trust (NYSEARCA: SPY) pulled back. 

Investors

Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals

Bristol Myers Squibb Company (NYSE: BMY) is on a buying spree, announcing two acquisitions in less than a week. 

On December 22, the pharma giant said it was acquiring Karuna Therapeutics Inc.

5 Biotech stocks tapping into unmet mental health treatment needs
5 Biotech stocks tapping into unmet mental health treatment needs

Anyone who has dealt with a mental illness or has a loved one who struggles with a mental illness knows how devastating these diseases are. However, a growing number of biotechnology companies are

BellRing Brands gets pumped on the Ozempic weight-loss trend
BellRing Brands gets pumped on the Ozempic weight-loss trend

Sports nutritional products maker BellRing Brands Inc. (NYSE: BRBR) has seen its stock surge to new all-time highs driven by the popularity of GLP-1 weight-loss medication usage. While the name of

Unlocking AI Investment Opportunities in Healthcare
Unlocking AI Investment Opportunities in Healthcare

In recent years, AI has gone from a niche industry housed mostly in research labs, academia, and large companies like Google to dominating the news cycle and driving incredible growth and value

Are the S&P 500's Biggest Q3 Losers Next Year's Winners?
Are the S&P 500's Biggest Q3 Losers Next Year's Winners?

What started out to be a promising third quarter for U.S. stocks turned into a dud. On the backs of artificial intelligence (AI) excitement, the S&P 500 stormed out of the gates in July only to

Could Ely Lilly Be the Best Pharma Stock to Own Now and Forever?
Could Ely Lilly Be the Best Pharma Stock to Own Now and Forever?

Pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) stock has been on a tear, trading up 57.7% year-to-date (YTD). The company is firing on all cylinders with its leading medications and a highly